Procurement
Expert Panel
Create New Account
Login
logo
Report store
Insights
Survey
Consulting
Book discovery call
logo

Bronchitis Treatment Market: Current Analysis and Forecast (2021-2027)

Region:Global

Product Code:UMHE21863

Download Sample Report
Published On

June 2022

Total pages

186

About the Report

The bronchitis treatment market is expected to witness a CAGR of around ~5% during the forecast period (2021-2027). Bronchitis is when the tubes that carry air to your lungs, called the bronchial tubes, get inflamed and swollen. It can be described as either acute bronchitis or chronic bronchitis. This is caused mainly due to the sedentary lifestyle, addiction to cigarette smoke and chemical pollutants. Furthermore, rapid growth of the geriatric population and significant rise in respiratory disorders such as asthma, and lung cancer, among others is expected to drive the demand for effective bronchitis treatment. For instance, according to the World Population Ageing Report 2019 by United Nations (UN), In 2019, there were 703 million persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050.

Due to the COVID-19 pandemic, the industry has witnessed a strong upward hike in the growth of the market. This is mainly due to the increase in covid testing during the pandemic. Additionally, Bronchitis refers to inflammation of the main airways of the lungs so patients with bronchitis may be at risk of serious illness. In addition, both bronchitis and COVID-19 affect the lungs. As per the experts from The Johns Hopkins Organization, in COVID-19-related bronchitis is an issue of an excessive amount of sputum produced in the airways, resulting in coughing and chest congestion. The sputum also narrows the airways, making breathing more difficult. The Centers for Disease Control and Prevention (CDC) also informs that the coronavirus may cause more severe illness in those with bronchitis and lung diseases. These factors are the main reasons for the market growth during the forecast period. In addition. Thus, the demand for Bronchitis treatment has increased phenomenally due to the COVID-19 pandemic.

Based on type, the market is classified into acute bronchitis and chronic bronchitis. Among them, in 2020, the acute category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising incidence of patients suffering from respiratory diseases, lung diseases, asthma, air pollution, and geriatric pollution. Additionally, the market growth is driven by the rapid growth of smoking, coupled with a rising geriatric population across the globe. In addition, breathing in air pollutants can irritate a patient's airways and may cause shortness of breath, coughing, wheezing, asthma episodes, and chest pain. For instance, according to the world health organization (WHO), 9 out of 10 people breathe air containing high levels of pollutants. In 2019, 99% of the world population was living in places where the WHO air quality guidelines levels were not met. Both the number of cases and the prevalence of pollution have been steadily increasing over the past few decades.

Based on drug class, the market is bifurcated into antibiotics, anti-inflammatory, bronchodilators, and others. Among them, in 2020, the bronchodilator category held a significant share in the market. Bronchodilators are drugs often used as aerosols to widen the air passages by relaxing the bronchial muscle. They are effective in helping older, children and adults with asthma. Furthermore, asthmatic bronchitis is an inflammatory condition that causes airways to narrow. For instance, according to the world health organization (WHO), Asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths.

Based on distribution channel, the market is bifurcated into hospital hospitals pharmacies, retail pharmacies, and others. In 2020, the hospital pharmacies accounted for the majority share during the forecast period owing to the increasing construction of hospitals, the large number of patients treated at hospitals, the availability of trained professionals, and a surge in the number of respiratory cases, in the hospital setting. According to, institute for Health Metrics and Evaluation (IHME), Chronic respiratory diseases were responsible for 71-1 million YLLs and 32-4 million YLDs in 2019. Chronic obstructive pulmonary disease (COPD) and asthma were the two largest contributors to the global respiratory disease burden.

For a better understanding of the market adoption of the Bronchitis treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Rest of Asia-Pacific); and the Rest of World. In 2020. North America held an extensive market share owing to the rising prevalence of bronchitis, awareness, and well-established medical infrastructure and facilities. However, APAC region has the fastest growth during the forecast period. This is mainly due to the increasing environmental pollution, rising geriatric population with various respiratory diseases, and growing prevalence of lung diseases.

Some of the major players operating in the market include AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, and Cadila Healthcare Limited.

Scope of the Report

Products

The bronchitis treatment market is expected to witness a CAGR of around aprox 5% during the forecast period .

Companies

AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, and Cadila Healthcare Limited

Table of Contents

1 MARKET INTRODUCTION

1.1. Market Definitions

1.2. Limitation

1.3. Stakeholders

1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Bronchitis treatment Market

2.2. Research Methodology of the Bronchitis treatment Market

2.3. Forecasting Method

2.4. Respondent Profile

2.5. Main Objective of the Bronchitis treatment Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 BRONCHITIS TREATMENT MARKET COVID-19 IMPACT

6 BRONCHITIS TREATMENT MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY TYPE

7.1. Acute Bronchitis

7.2. Chronic Bronchitis

8 MARKET INSIGHTS DRUG CLASS

8.1. Antibiotics

8.2. Anti-inflammatory

8.3. Bronchodilator

8.4. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

9.1. Hospital Pharmacies

9.2. Retail Pharmacies

9.3. Others

10 MARKET INSIGHTS BY REGION

10.1. North America

10.1.1. U.S.

10.1.2. Canada

10.1.3. Rest of North America

10.2. Europe

10.2.1. Germany

10.2.2. United Kingdom

10.2.3. France

10.2.4. Spain

10.2.5. Italy

10.2.6. Rest of Europe

10.3. Asia-Pacific

10.3.1. China

10.3.2. Japan

10.3.3. India

10.3.4. Rest of Asia-Pacific

10.4. Rest of World

11 BRONCHITIS TREATMENT MARKET DYNAMICS

11.1. Market Drivers

11.2. Market Challenges

11.3. Impact Analysis

12 BRONCHITIS TREATMENT MARKET OPPORTUNITIES

13 BRONCHITIS TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

14.1. Demand Side Analysis

14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

16.1. Competitive Landscape

16.1.1. Porter's Five Forces Analysis

17 COMPANY PROFILED

17.1. AstraZeneca PLC

17.2. Novartis AG

17.3. GlaxoSmithKline PLC

17.4. Dr. Reddy's Laboratories Ltd

17.5. Sanofi SA

17.6. Boehringer Ingelheim International GmbH

17.7. Pfizer Inc.

17.8. Melinta Therapeutics

17.9. Lupin Limited

17.10. Cadila Healthcare Limited

18 DISCLAIMER

Research Methodology

Why Buy From Us?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022